Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Eyes Food Traceability Marketplace

NEW YORK, Dec. 31 (GenomeWeb News) -- Orchid BioSciences plans to enter the DNA-based food traceability market, the company said in a statement today.

 

The Princeton, NJ-based company, which currently conducts a food safety business that focuses on disease-susceptibility and DNA identity testing of animals, said it plans to take advantage of its existing laboratory infrastructure, which this year tested over a half a million sheep in a high-throughput facility in the UK, and its SNP genotyping processes, to begin the new marketing effort.

 

Orchid is a market leader in providing susceptibility genotyping testing for scrapie, a neurodegenerative disease characterized by the accumulation of prions, an abnormal protein in the brains of affected sheep, similar to bovine spongiform encephalopathy in cattle, and Creutzfeldt-Jakob disease in humans.

 

The company said it plans to make its first meat identification assays available as part of its services in 2004.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.